PURPOSE: Proton therapy is currently used in the management of pediatric tumors to decrease late toxicities. However, one of the criticisms of proton therapy is the limited data regarding efficacy on disease control. The purpose of this study was to examine local and distant control rates after proton therapy for neuroblastoma. METHODS AND MATERIALS: Eighteen patients with high-risk (n = 16) and locally recurrent neuroblastoma (n = 2) were treated with curative intent and received proton therapy to the primary site and up to three post-induction MIBG-avid metastatic sites. Primary sites (n = 18) were treated to 21-36 Gy (relative biological effectiveness [RBE]), and metastatic sites (n = 16) were treated to 21-24 Gy (RBE). Local control and survival rates were calculated using the Kaplan-Meier method. RESULTS: With a median follow-up of 60.2 months, two- and five-year local control rates at the irradiated primary site were 94% and 87%, respectively. No failures at irradiated distant metastatic sites were observed. The five-year progression-free survival (PFS) was 64%, and the five-year overall survival (OS) was 94%. The extent of surgical resection was not associated with local control, PFS, or OS. No radiation-related nephropathy or hepatopathy was reported. CONCLUSIONS: Excellent local control was achieved using proton therapy to the primary and post-induction MIBG-positive distant sites. The predominant site of failure is progression in post-induction non-MIBG-avid distant sites. Although proton therapy provides high rates of local control with acceptable toxicity for neuroblastoma, further advances in systemic therapy are needed for the improved control of systemic disease.
PURPOSE: Proton therapy is currently used in the management of pediatric tumors to decrease late toxicities. However, one of the criticisms of proton therapy is the limited data regarding efficacy on disease control. The purpose of this study was to examine local and distant control rates after proton therapy for neuroblastoma. METHODS AND MATERIALS: Eighteen patients with high-risk (n = 16) and locally recurrent neuroblastoma (n = 2) were treated with curative intent and received proton therapy to the primary site and up to three post-induction MIBG-avid metastatic sites. Primary sites (n = 18) were treated to 21-36 Gy (relative biological effectiveness [RBE]), and metastatic sites (n = 16) were treated to 21-24 Gy (RBE). Local control and survival rates were calculated using the Kaplan-Meier method. RESULTS: With a median follow-up of 60.2 months, two- and five-year local control rates at the irradiated primary site were 94% and 87%, respectively. No failures at irradiated distant metastatic sites were observed. The five-year progression-free survival (PFS) was 64%, and the five-year overall survival (OS) was 94%. The extent of surgical resection was not associated with local control, PFS, or OS. No radiation-related nephropathy or hepatopathy was reported. CONCLUSIONS: Excellent local control was achieved using proton therapy to the primary and post-induction MIBG-positive distant sites. The predominant site of failure is progression in post-induction non-MIBG-avid distant sites. Although proton therapy provides high rates of local control with acceptable toxicity for neuroblastoma, further advances in systemic therapy are needed for the improved control of systemic disease.
Authors: Richard Li; Alexei Polishchuk; Steven DuBois; Randall Hawkins; Stephanie W Lee; Rochelle Bagatell; Suzanne Shusterman; Christine Hill-Kayser; Hasan Al-Sayegh; Lisa Diller; Daphne A Haas-Kogan; Katherine K Matthay; Wendy B London; Karen J Marcus Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-08 Impact factor: 7.038
Authors: Daniel von Allmen; Andrew M Davidoff; Wendy B London; Collin Van Ryn; Daphne A Haas-Kogan; Susan G Kreissman; Geetika Khanna; Nancy Rosen; Julie R Park; Michael P La Quaglia Journal: J Clin Oncol Date: 2016-11-21 Impact factor: 44.544
Authors: Alexei L Polishchuk; Richard Li; Christine Hill-Kayser; Anthony Little; Randall A Hawkins; Jeffrey Hamilton; Michael Lau; Hung Chi Tran; Caron Strahlendorf; Richard S Lemons; Vivian Weinberg; Katherine K Matthay; Steven G DuBois; Karen J Marcus; Rochelle Bagatell; Daphne A Haas-Kogan Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-24 Impact factor: 7.038
Authors: Thomas H Beckham; Dana L Casey; Michael P LaQuaglia; Brian H Kushner; Shakeel Modak; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2017-04-11 Impact factor: 7.038
Authors: Dana L Casey; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden Journal: Pediatr Blood Cancer Date: 2018-02-22 Impact factor: 3.167
Authors: Matthew J Ferris; Hasan Danish; Jeffrey M Switchenko; Claudia Deng; Bradley A George; Kelly C Goldsmith; Karen J Wasilewski; W Thomas Cash; Mohammad K Khan; Bree R Eaton; Natia Esiashvili Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-27 Impact factor: 7.038
Authors: Christine Hill-Kayser; Zelig Tochner; Stefan Both; Robert Lustig; Anne Reilly; Naomi Balamuth; Richard Womer; John Maris; Stephen Grupp; Rochelle Bagatell Journal: Pediatr Blood Cancer Date: 2013-06-04 Impact factor: 3.167
Authors: Clayton B Hess; Daniel J Indelicato; Arnold C Paulino; William F Hartsell; Christine E Hill-Kayser; Stephanie M Perkins; Anita Mahajan; Nadia N Laack; Ralph P Ermoian; Andrew L Chang; Suzanne L Wolden; Victor S Mangona; Young Kwok; John C Breneman; John P Perentesis; Sara L Gallotto; Elizabeth A Weyman; Benjamin V M Bajaj; Miranda P Lawell; Beow Y Yeap; Torunn I Yock Journal: Front Oncol Date: 2018-05-24 Impact factor: 6.244
Authors: Danny Jazmati; Sarina Butzer; Barbara Hero; Dalia Ahmad Khalil; Julien Merta; Christian Bäumer; Gina Plum; Jörg Fuchs; Friederike Koerber; Theresa Steinmeier; Sarah Peters; Jerome Doyen; Theresa Thole; Matthias Schmidt; Christoph Blase; Stephan Tippelt; Angelika Eggert; Rudolf Schwarz; Thorsten Simon; Beate Timmermann Journal: Front Oncol Date: 2021-01-20 Impact factor: 6.244